Ipsen
| Company type | Public |
|---|---|
| Euronext Paris: IPN
CAC Mid 60 Component | |
| ISIN | FR0010259150 |
| Industry | Pharmaceutical |
| Founded | 1929 |
| Founder | Henri Beaufour |
| Headquarters | Boulogne-Billancourt, France |
Key people | Marc de Garidel (Non-executive Chairman) David Loew (Chief Executive Officer) |
| Products | List of medicines |
| Revenue | €3.128 billion(2023) |
| €1.001 billion(2023) | |
| €647 million(2023) | |
Number of employees | 5,700 |
| Website | www.ipsen.com |
| Footnotes / references | |
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.